CCR6 and colitis: Moving from these grounds, our group has recently developed compound MR120 (Figure 1), a small and selective CCR6 antagonist whose anti-inflammatory efficacy has been proved by us in three different models of intestinal inflammation: subacute TNBS-induced colitis, considered a preclinical model of Crohn’s disease [14], zymosan-induced peritonitis, reproducing acute inflammation associated with strong native immune responses [14], and chronic DSS-induced colitis, a model able to more closely mimic the typically alternating phases of remission and exacerbation of human IBD [15].